Evolva raises CHF 31.3 million in oversubscribed share issue

Preliminary 2012 loss lower than expected

Reinach, Switzerland, 20 March 2013 — Evolva Holding SA (SIX: EVE, “Evolva”) today announced that its offering (announced on 6 March 2013) was fully subscribed by existing and new shareholders. The offering provides Evolva with gross proceeds of CHF 31.3 million before transaction costs.

The shareholders were offered the opportunity to subscribe to three new shares for every ten shares held, at a subscription price of CHF 0.60 each. 24,181,122 Shares were taken up pursuant to the exercise of rights, equivalent to 46.3% of the total of 52,214,472 shares available under the offering.

After allowing for the exercise of rights by existing shareholders, approximately 28 million new shares were placed with Cargill, Inc. and institutional investors. Due to strong demand, not all pre-commitments by new investors could be satisfied in the allocation.

The capital increase also included the issuance of 14 million treasury shares to Evolva. These will be used to satisfy part of Evolva’s obligations towards APIDC/Ventureast (conversion agreement as explained in the 2011 annual report, page 28) and the SEDA arrangement with YA Global (see press release 11 August 2011).

The new shares, arising from the capital increase, are expected to be entered in the Commercial Register today, 20 March 2013, and listed on SIX Swiss Exchange on 21 March 2013. Settlement and delivery of the new shares is expected to take place on 25 March 2013.

Based on the preliminary consolidated accounts for 2012, Evolva expects a net loss of approximately CHF 17 million, compared to a loss of CHF 22.9 million in 2011. The loss of 2012 is substantially lower than our forecast of November 2012, partly driven by a one-off, non-cash release of the contingent consideration in connection with the acquisition of Abunda. The 2012 annual report will be published on 9 April 2013.

– Ends –

Download press release in English
Download press release in German

About Evolva

Evolva’s mission is to discover and provide innovative, sustainable ingredients for health, nutrition and wellness. Evolva uses biosynthetic and evolutionary technologies to create and optimise small molecule compounds and their production routes. We are active in consumer healthcare and nutrition as well as in pharma. In both areas we have partnered projects as well as proprietary programmes. For more information see www.evolva.com.

Contact Details

Neil Goldsmith, CEO Jakob Dynnes Hansen, CFO Paul Verbraeken, IR
neilg@evolva.com jakobdh@evolva.com paulv@evolva.com
+ 41 61 485 2005 + 41 61 485 2034 + 41 61 485 2035

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.